Astrana Health Q2 2026 adjusted EPS more than doubles to $0.80; revenue rises 49% to $972.5 million vs year-ago quarter

• Astrana Health Q2 2026 revenue rose 49% to $972.5 million, while net income attributable to shareholders more than doubled to $19.7 million.
• Adjusted EBITDA (non-GAAP) climbed 43% to $68.9 million; adjusted EPS (non-GAAP, diluted) increased 45% to $0.80.
• G&A improved 210 basis points to 5.6% of revenue, helped by continued deployment of proprietary AI-enabled tools.
• Served about 1.5 million value-based patients, with about 1.2 million members in Care Partners; 81% of Q2 capitation revenue came from full-risk arrangements.
• Kept FY 2026 revenue outlook at $3.8 billion-$4.1 billion, while raising adjusted EBITDA (non-GAAP) guidance to $255 million-$280 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astrana Health Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.